Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection
IntroductionThis study compares the immune responses of healthy individuals, with or without prior SARS-CoV-2 infection, following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca).MethodsA total of 134 volunteers were analyzed: 71 recipients of Comirnaty (36 with prior infection) and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612288/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839626610610798592 |
|---|---|
| author | Zdzisława Kondera-Anasz Emilia Justyna Morawiec Emilia Justyna Morawiec Roksana Duszkiewicz Filip Hajdrowski Andrzej Wiczkowski |
| author_facet | Zdzisława Kondera-Anasz Emilia Justyna Morawiec Emilia Justyna Morawiec Roksana Duszkiewicz Filip Hajdrowski Andrzej Wiczkowski |
| author_sort | Zdzisława Kondera-Anasz |
| collection | DOAJ |
| description | IntroductionThis study compares the immune responses of healthy individuals, with or without prior SARS-CoV-2 infection, following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca).MethodsA total of 134 volunteers were analyzed: 71 recipients of Comirnaty (36 with prior infection) and 63 recipients of Vaxzevria (33 with prior infection). Immune responses were assessed after the second and third doses by measuring anti-SARS-CoV-2 IgG levels and interferon-gamma (IFN-γ) production using an IGRA assay.ResultsSignificant differences were observed in IgG and IFN-γ concentrations between the vaccine groups. Higher IgG and IFN-γ levels were noted in individuals vaccinated with Comirnaty, especially after the third dose, indicating a stronger T-cell-mediated response. Prior infection enhanced immune responses, as previously infected individuals showed elevated IgG and IFN-γ levels. Hematological analysis revealed differences in immune activation patterns between vaccines, including variations in white blood cell counts, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR).DiscussionThese findings highlight distinct vaccine-induced immune responses depending on vaccine type, prior infection status, and number of doses administered. They contribute to understanding the differential immune memory elicited by mRNA-based and adenoviral vector-based vaccines and emphasize the importance of booster doses in maintaining robust immunity against SARS-CoV-2. |
| format | Article |
| id | doaj-art-1ed15c34b0a74b4fb980a7a5dd5e1af3 |
| institution | Matheson Library |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-1ed15c34b0a74b4fb980a7a5dd5e1af32025-07-17T05:24:05ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.16122881612288Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infectionZdzisława Kondera-Anasz0Emilia Justyna Morawiec1Emilia Justyna Morawiec2Roksana Duszkiewicz3Filip Hajdrowski4Andrzej Wiczkowski5Department of Immunology, Faculty of Medicine in Zabrze, Academy of Silesia, Katowice, PolandDepartment of Microbiology, Faculty of Medicine in Zabrze, Academy of Silesia, Katowice, PolandLaboratory of Molecular Biology and Virology, Gyncentrum, Katowice, PolandDepartment of Immunology, Faculty of Medicine in Zabrze, Academy of Silesia, Katowice, PolandDepartment of Immunology, Faculty of Medicine in Zabrze, Academy of Silesia, Katowice, PolandDepartment of Microbiology, Faculty of Medicine in Zabrze, Academy of Silesia, Katowice, PolandIntroductionThis study compares the immune responses of healthy individuals, with or without prior SARS-CoV-2 infection, following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca).MethodsA total of 134 volunteers were analyzed: 71 recipients of Comirnaty (36 with prior infection) and 63 recipients of Vaxzevria (33 with prior infection). Immune responses were assessed after the second and third doses by measuring anti-SARS-CoV-2 IgG levels and interferon-gamma (IFN-γ) production using an IGRA assay.ResultsSignificant differences were observed in IgG and IFN-γ concentrations between the vaccine groups. Higher IgG and IFN-γ levels were noted in individuals vaccinated with Comirnaty, especially after the third dose, indicating a stronger T-cell-mediated response. Prior infection enhanced immune responses, as previously infected individuals showed elevated IgG and IFN-γ levels. Hematological analysis revealed differences in immune activation patterns between vaccines, including variations in white blood cell counts, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR).DiscussionThese findings highlight distinct vaccine-induced immune responses depending on vaccine type, prior infection status, and number of doses administered. They contribute to understanding the differential immune memory elicited by mRNA-based and adenoviral vector-based vaccines and emphasize the importance of booster doses in maintaining robust immunity against SARS-CoV-2.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612288/fullComirnaty BNT162b2Vaxzevria ChAdOx1-SCOVID-19 vaccinesanti-SARS-CoV-2 IgGinterferon-gammaimmune response |
| spellingShingle | Zdzisława Kondera-Anasz Emilia Justyna Morawiec Emilia Justyna Morawiec Roksana Duszkiewicz Filip Hajdrowski Andrzej Wiczkowski Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection Frontiers in Immunology Comirnaty BNT162b2 Vaxzevria ChAdOx1-S COVID-19 vaccines anti-SARS-CoV-2 IgG interferon-gamma immune response |
| title | Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection |
| title_full | Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection |
| title_fullStr | Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection |
| title_full_unstemmed | Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection |
| title_short | Comparison of SARS-CoV-2 immune responses following vaccination with Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) in healthy individuals with or without prior SARS-CoV-2 infection |
| title_sort | comparison of sars cov 2 immune responses following vaccination with comirnaty pfizer and vaxzevria astrazeneca in healthy individuals with or without prior sars cov 2 infection |
| topic | Comirnaty BNT162b2 Vaxzevria ChAdOx1-S COVID-19 vaccines anti-SARS-CoV-2 IgG interferon-gamma immune response |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1612288/full |
| work_keys_str_mv | AT zdzisławakonderaanasz comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection AT emiliajustynamorawiec comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection AT emiliajustynamorawiec comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection AT roksanaduszkiewicz comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection AT filiphajdrowski comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection AT andrzejwiczkowski comparisonofsarscov2immuneresponsesfollowingvaccinationwithcomirnatypfizerandvaxzevriaastrazenecainhealthyindividualswithorwithoutpriorsarscov2infection |